Roche (RHHBY) is approaching an agreement to acquire the gene therapy player Spark Therapeutics (once) for $ 5 billion that the Swiss drugmaker appears to expand his hemophilia treatments.
The agreement will allow Roche access to Sparks pipeline of gene products, including a Pfizer (PFE) partner therapy for hemophilia B and a wholly-owned hemophilia A treatment. Both gene therapies are currently in phase 3 testing.
Spark also has the first food and drug treatment approved gene therapy, Luxturna. Gene therapy was approved in 2017 to treat a rarely inherited eye disorder that often leads to blindness.
Representatives of Spark and Roche concluded comment on e-mail Saturday to Investor's Business Daily.
Betting On Hemophilia Treatments
Roche is betting great on hemophilia treatments with its substance called Hemlibra. Hemlibra is a hemophilia A treatment. Last month, Roche said Hemlibra generated around $ 154 million in 2018 US sales. Global sales were around $ 224 million.
William Anderson, who heads Roche's pharmaceutical division, marked Hemlibra's strong record on the company's quarterly interview in January. 19659004] "You see mainly that we've almost doubled sales every quarter," he told analysts. "I want to say that early reading is that it is not a type of patient receiving Hemlibra."
Gene therapy companies also invest in this space. BioMarin Pharmaceutical (BMRN) and Spark Work on Hemophilia A Treatments, while UniQure (QURE) develops hemophilia B treatments. Pfizer also collaborates with Spark on a hemophilia B gene therapy.
Last year, an ARK Invest analyst told IBD that she believed hemophilia treatments could be a $ 26 billion opportunity by 2025.
Biotech Takeovers in 2019
Takeovers in the Biotech space have been rampant in 2019.  Bristol-Myers Squibb (BMY) spends $ 74 billion to buy Celgene (CELG). Eli Lilly (LLY) plans to pay $ 8 billion to Loxo Oncology (LOXO). GlaxoSmithKline (GSK) agreed to buy Tesaro for $ 5.1 billion.
Analysts say large biotech companies can look at small and medium-sized biotechnologies to maintain slowing sales with an infusion of new products. 19659004] YOU MUST LIKE:
Can this biotechnology release the sales team with strong gene therapy?
The fastest growing health care providers all have this in common
Get Free IBD Newsletter: Market Prep | Tech Report | How to invest